Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2350298-92-7
Molecular formula
C6434H9922N1718O2012S46
Molecular weight
145007 g/mol
Drug class
Programmed cell death protein 1 (PD-1)-blocking monoclonal antibodyimmune checkpoint inhibitor
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, relieving PD-1-mediated inhibitory signalling and restoring antitumour T-cell activity.
Indications / reported uses
In combination with gemcitabine and cisplatin or carboplatin for first-line treatment of adults with recurrent or metastatic non-keratinising nasopharyngeal carcinoma.
As monotherapy for adults with metastatic non-keratinising nasopharyngeal carcinoma that has progressed on or after platinum-based chemotherapy and at least one other prior line of therapy, under the US indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Penpulimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Penpulimab Permitted Daily Exposure (PDE) report (the Penpulimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Penpulimab Occupational Exposure Limit (OEL) report (the Penpulimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.